GlassScriptPhysician profile
Ashlee Blakeslee
NPI 1508398439
$4,295.39
in general payments reported to CMS, 2019-2025
28 companies · $844 in 2025
The $844 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $511 · 2022: $976 · 2023: $935 · 2024: $1,029 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,805 · Education: $3.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,805.07 |
| Education | $3.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $737.58 | 2021-2025 | |
| Pfizer INC. | $543.70 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $534.09 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $318.79 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $295.25 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $275.62 | 2021-2025 | Farxiga, Lokelma |
| Astellas Pharma US INC | $231.09 | 2021-2022 | |
| Amgen INC. | $213.87 | 2021-2025 | Repatha, Repatha |
| Novo Nordisk INC | $197.23 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $184.80 | 2022-2025 | Varithena Administration Pack, Emblem Mri S-Icd, Watchman Flx |
| Lexicon Pharmaceuticals, INC. | $140.52 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $83.27 | 2021-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $78.95 | 2023-2024 | |
| Amarin Pharma, INC. | $63.09 | 2021 | |
| Abbott Laboratories | $58.55 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $47.24 | 2025 | |
| Edwards Lifesciences Corporation | $43.72 | 2025 | Sapien 3 Ultra Resilia |
| Kiniksa Pharmaceuticals International, Plc | $36.10 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $33.18 | 2021-2022 | |
| Axsome Therapeutics, INC. | $28.57 | 2023 | Sunosi |
| Esperion Therapeutics, INC. | $24.28 | 2021 | |
| Scpharmaceuticals INC. | $24.11 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $21.29 | 2023 | Arcalyst |
| Glaxosmithkline, LLC. | $18.70 | 2025 | Arexvy, Shingrix |
| Actelion Pharmaceuticals US, INC. | $17.34 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.52 | 2022 | |
| Vital Connect, INC | $14.24 | 2023 | Vitalpatch Rtm |
| Baxter Healthcare | $13.70 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Blakeslee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.